Form 4: Elanco Director Receives Annual Equity Award

Elanco Animal Health Inc. Director Lawrence Kurzius was granted 10,314 deferred stock units as an annual equity award.

Summary

• Lawrence Erik Kurzius, a Director of Elanco Animal Health Inc. (ELAN), acquired 10,314 shares of common stock.
• The transaction occurred on November 28, 2025, at a price of $0 per share.
• This acquisition represents a grant of deferred stock units as an annual equity award for non-employee board members.
• Following this transaction, Kurzius beneficially owns 121,773 shares of Elanco common stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event, indicating stability in governance and standard practice, but not a significant market-moving event on its own.

Positives

• The grant of deferred stock units to a director aligns director interests with shareholder value.
• The award is part of the annual equity compensation for non-employee board members, indicating standard corporate governance practices.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing for a director's equity compensation, common across publicly traded companies in all sectors, including the animal health industry. It reflects standard practices for aligning board member incentives with company performance.

Comparison to Industry Standards

• The grant of deferred stock units as an annual equity award to non-employee directors is a common practice in corporate governance across various industries, including the pharmaceutical and animal health sectors. Companies like Zoetis Inc. (ZTS) and IDEXX Laboratories, Inc. (IDXX) also utilize similar equity-based compensation structures for their independent directors to foster long-term alignment with shareholder interests.
• A $0 transaction price for such grants is standard, as these are typically awards for service rather than open market purchases.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with long-term shareholder value.

Key Dates

Recommendation

This Form 4 filing reports a routine annual equity award to a non-employee director. Such grants are standard practice for director compensation and do not typically signal a change in the company's fundamental outlook or operational performance. Therefore, it does not provide new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation based solely on this filing.

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Transaction, Stock Grant, Director Compensation, Equity Award, Deferred Stock Units